PRGO

PERRIGO Co plc

Pharmaceutical Preparations · SIC 2834CIK 1585364Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$4.25B

Net Income FY2025

$(1.43B)

EPS (Basic, as reported)

$-10.29

Net Margin FY2025

-33.5%

ROE FY2025

-48.6%

Total Equity

$2.94B

Shares Out

139M

Business description

PERRIGO Co plc — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2012–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 5,281 → 4,253 -2.4% CAGR

Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue5,2814,9464,7324,8375,0634,1394,4524,6564,3734,253

Cost of revenue(3,229)(2,967)(2,900)(3,064)(3,248)(2,722)(2,996)(2,975)(2,831)(2,759)

Gross profit2,0521,9801,8321,7731,8151,4161,4551,6801,5431,495

Research & development(184)(168)(219)(187)(178)(122)(123)(122)(112)(95)

Selling & marketing(665)(598)(596)(567)(579)(536)(585)(642)(547)(526)

General & administrative(452)(461)(436)(503)(496)(482)(512)(522)(468)(436)

Total operating expenses(4,051)(1,381)(1,595)(1,568)(1,700)(1,006)(1,376)(1,528)(1,430)(2,617)

Operating income(2,000)59823720511541079152113(1,122)

Other income (expense), net(23)10(6)66(17)(27)(53)101(13)

Pre-tax income(4,848)280291——259(139)(8)(81)(1,298)

Income tax expense(835)(160)(160)(25)(13)(390)(8)(4)(80)(104)

Net income(4,013)120131146(163)(69)(141)(13)(172)(1,425)

EPS — basic($28.01)$0.84$0.95$1.07($1.19)($0.52)($1.04)($0.09)($1.25)($10.29)

EPS — diluted($28.01)$0.84$0.95$1.07($1.19)($0.52)($1.04)($0.09)($1.25)($10.29)

Shares outstanding — basic (M)143142138136136134135135137139

Shares outstanding — diluted (M)143143138137136134135135137139

Showing the latest 10 of 14 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.